SCHEDULE: Commodore Capital Reduces Celldex Stake to 4.6%
Beneficial Ownership Report (Amendment)
Commodore Capital LP and Commodore Capital Master LP have disclosed a beneficial ownership of 4.6% in Celldex Therapeutics, Inc. common stock as of September 30, 2025.
Summary
- Commodore Capital LP and Commodore Capital Master LP reported beneficial ownership of 3,028,335 shares of Celldex Therapeutics, Inc. common stock.
- This represents 4.6% of the class of securities, based on 66,446,846 common shares outstanding as of September 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 10, 2025.
- Commodore Capital LP, a Delaware entity, serves as the investment manager for Commodore Capital Master LP, a Cayman Islands entity.
- Michael Kramarz and Robert Egen Atkinson, managing partners of Commodore Capital LP, exercise investment discretion over these securities.
- The reporting persons hold shared voting power and shared dispositive power over all 3,028,335 beneficially owned shares.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently suggest a positive or negative sentiment regarding the issuer's performance or prospects.
Future Outlook
NA
Management Comments
- Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion with respect to the reported securities.
Industry Context
NA
Stakeholder Impact
- Shareholders are informed of a significant institutional investor's updated position in Celldex Therapeutics, Inc., which now represents less than 5% of the outstanding common stock.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires filing of this statement, representing the ownership calculation date. |
| 11/10/2025 | Date Celldex Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, providing the outstanding share count. |
| 11/14/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Celldex Therapeutics, Commodore Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment Manager
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.